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Telomerase is a reverse transcriptase that maintains telomeres by adding telomeric TTAGGG repeats to the ends of human
chromosomes. The aim of this study was to evaluate quantitatively the mRNA expression of telomerase catalytic subunit (hTERT) in
different types of intracranial tumours in relation to their histologic pattern and grade and correlate it with progression-free (PFS) and
overall survival (OS) of patients. Human telomerase reverse transcriptase mRNA levels were estimated by the use of real time RT–
PCR in 68 samples of intracranial tumours. It revealed statistical correlation between hTERT mRNA expression levels and the grade
of the tumours (Po0.001). Patients having negative expression of hTERT mRNA had statistically longer PFS (P¼0.031) and OS
(P¼0.047). Cox univariate regression analysis revealed that hTERT mRNA-positive patients had a high and statistically significant risk
of relapse (hazard ratio (HR) of 2.24 and P¼0.038). In the Cox multivariate regression model, the levels of hTERT mRNA were
adjusted for tumour grade and patients age, and since there was statistically significant relationship between the levels of hTERT
mRNA and the grade of the tumours (P¼0.003 or P¼0.006, respectively), hTERT mRNA levels could not be considered as an
independent prognostic factor for PFS or OS.
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Most eukaryotic cells that can divide in vivo cannot do so
indefinitely. The process that limits the proliferative potential of
cells has been termed cellular or replicative senescence. The
mechanism by which cells sense the number of divisions they have
completed appears to depend, at least in part, on the length of their
telomeres (Campisi, 1997). Telomeres are long repetitive nucleo-
tide sequences at both ends of chromosomes that consist of
hundreds to thousands of tandem repeats of the sequence
TTAGGG. Their primary role is to protect chromosome ends
from recombination, fusion and DNA degradation. Telomeres
shorten progressively with each round of cell division as a result of
the inability of DNA polymerases to replicate the 50 end of linear
DNA, and erosion of these sequences beyond a critical point is
thought to signal cell cycle arrest and entry into cellular senescence
(O’Reilly et al, 1999). Telomerase is a ribonucleoprotein poly-
merase composed of an integral RNA component (hTR) (Feng
et al, 1995) and several protein components, including the reverse
transcriptase subunit human telomerase reverse transcriptase
(hTERT) (Kilian et al, 1997; Nakayama et al, 1998). The RNA
component hTR contains the template for the reverse transcription
of telomeres, and hTERT is the reverse transcriptase that catalyses
this reaction. The RNA component hTR and hTERT are
indispensable for telomerase activity, and expression of these
subunits in vitro leads to the formation of a functional telomerase
enzyme (Weinrich et al, 1997; Counter et al, 1998; Nakayama et al,
1998). In vertebrate organisms, telomerase activation is a
mechanism known to stabilise the loss of telomeres. Most somatic
cells, regardless of their rate of proliferation undergo a steady-state
rate of telomere loss and do not posses detectable telomerase
activity. In contrast, all immortal cells examined to date show no
loss of telomere length or sequence with division, suggesting that
maintenance of telomeres is required for cells to escape from
replicative senescence and proliferate indefinitely (Kim, 1997;
Dhaene et al, 2000). Recent studies in which the gene encoding
hTERT was introduced into normal human cells that lack hTERT
resulted in reconstitution of telomerase activity, maintenance of
telomeres, extension of replicative capacity and transformation of
normal cells into cancer cells (Hahn et al, 1999). In humans,
telomerase has been detected in most types of cancer, including
those of the brain (Kotoula et al, 2004; Novakovic et al, 2004;
Snuders et al, 2004), suggesting a role for telomerase in sustaining
proliferative capacity to cells, which is a requirement for
progression towards malignancy. It is usually not detected in
normal somatic cells, except for proliferating stem cells, during
embryonic development, and in adult germline tissues.
Malignant gliomas account for the largest number of primary
brain tumours in adults. Even with best conventional therapy, the
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sprognosis is poor. Most patients do not survive beyond 1 year after
the diagnosis of glioblastoma multiforme, for more than 5 years
with anaplastic astrocytoma, and usually for not more than 10
years with oligodendroglioma. Brain tumours were one of the first
systems in which telomerase activity was assessed as a marker of
malignancy (Langford et al, 1995). To date, it is generally accepted
that high telomerase activity levels characterise high-grade gliomas
(Le et al, 1998; Falchetti et al, 1999; Huang et al, 1999; Harada et al,
2000; Sugita et al, 2000); however, there is no agreement on the
distinctive or prognostic value of this parameter (Kleinschmidt-
Demasters et al, 2000), while telomerase positivity rates vary
extensively among the different studies (23.6–100%) (Langford
et al, 1995; Chong et al, 1998; Le et al, 1998; Falchetti et al, 1999;
Huang et al, 1999; Harada et al, 2000; Kleinschmidt-Demasters
et al, 2000; Sugita et al, 2000).
Meningiomas are estimated to constitute up to 25% of primary
intracranial tumours (Kleihues and Cavenee, 2000). They are
typically benign tumours, but the incidence of growth at
inoperable sites and recurrence complicate surgical management.
The limited understanding of aetiology and growth of these
tumours has hindered the development of an adjuvant therapy.
The hypotheses that reactivation of telomerase is required to
maintain tumour growth (Kim et al, 1994) or may play a critical
role in the progression or maintenance of the malignant phenotype
(Rhyu, 1995) are in conflict with findings in benign meningiomas.
Several studies have reported that telomerase activity is present in
the vast majority of malignant brain tumours, while enzyme
activity could not be detected in benign meningiomas (Carroll
et al, 1999; Falchetti et al, 1999; Hiraga et al, 1998; Sano et al, 1998;
Cabuy and de Ridder 2001; Boldrini et al, 2003).
In the present study, the expression level of hTERT mRNA was
determined by the method of real-time quantitative RT–PCR in a
cohort of 68 intracranial tumours, consisting of 34 malignant
gliomas, 18 meningiomas, seven metastatic tumours to the brain
and seven miscellaneous intracranial tumours. Real-time quanti-
tative RT–PCR methodology is a modern technique that can
provide significant and quantitative information about gene
transcripts in an automated, rapid, versatile and cost-effective
way. Furthermore, the present study examines exclusively Greek
population leaving permanently through out their lives at the
island of Crete.
MATERIALS AND METHODS
Patients and samples
The 68 brain tumour samples used in this study were resected
surgically from 67 patients at the Department of Neurosurgery of
the University Hospital of Heraclion, Crete, between 1999 and
2003. Follow-up information was available for 60 of them.
Histologic diagnoses and grading of tumours were made based
on the revised World Health Organization (WHO) classification of
brain tumours (WHO, 2000). A total of 36 samples were
neuroepithelial tumours (17 glioblastomas multiforme (grade
IV); eight astrocytomas (five grade I, one grade II, two grade
III,); two myeloblastomas (grade IV); three oligodendrogliomas
(grade III); two ependymomas (one grade I and one grade II); four
neurinomas (one central neurinoma grade I and three acoustic
neurinomas, grade I)); 18 samples were meningeal tumours
(meningiomas); seven miscellaneous brain tumors (one pituitary
adenoma; one non-Hodgkin B-lymphoma; one osteoma; one
cholosteatoma; one hemangioblastoma; one choroid plexus
papilloma; one nonspecific inflammation) and seven metastatic
brain tumours (four from lung adenocarcinoma, two from breast
adenocarcinoma and one from melanoma) (Table 1). For a
recurrent glioblastoma multiform case, both primary and recur-
rent tumour was examined. In addition, adjacent normal brain
tissues, which were obtained by corticotomy while attempting to
reach the tumours of two primary glioblastomas multiform
patients, were used as controls. The controls were sufficiently
separated from the tumours and appeared normal to the naked
eye. All cases under study came from total surgical removal. No
chemotherapy or radiotherapy was administered before surgery.
Investigations were carried out in accordance with the ethical
standards of the Helsinki Declaration of 1975, as revised in 1983.
Informed consent was obtained from all patients for the scientific
analysis of tumour samples.
Specimens for the analysis of hTERT and histologic observation
were taken from the same general region of the tumour during
surgery. Immediately after surgery, the samples were snap-frozen
and stored in liquid nitrogen until RNA extraction. Furthermore,
the patient with the recurrent glioblastoma multiforme was
previously irradiated locally with a dose of 60 grays (Gy) and
given 3mgm
 2 dose of cisplatin. All patients with primary
glioblastoma multiforme and anaplastic astrocytoma also under-
went irradiation and were given cisplatin (2–4mgm
 2) after
surgery.
Total RNA isolation
Total RNA isolation was performed using the Trizol LS reagent
(Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s
instructions. All of the preparation and handling steps of RNA
took place in a laminar flow hood, under RNAse-free conditions.
The isolated RNA was dissolved in RNA storage buffer (Ambion;
Houston, TX, USA) and stored at  801C until used. RNA
concentration was determined by absorbance readings at 260nm
with the HITACHI UV-VIS (U-2000) spectrophotometer. RNA
Table 1 human telomerase reverse transcriptase (hTERT)-positive
expression in 68 intracranial tumours
Histology (WHO grade) n
+ hTERT
expression (n)%
Neuroepithelial tumours
Glioblastoma grade IV 17 10 58.8
Myeloblastoma grade IV 2 2 100
Astrocytoma grade III 2 2 100
Astrocytoma grade II 1 1 100
Astrocytoma grade I 5 1 20
Oligodendroglioma grade III 3 2 66.6
Ependymoma grade I 1 0 0
Ependymoma grade II 1 1 100
Neurinoma grade I 4 1 25
Meningeal tumours
Meningioma grade I 18 4 22.22
Miscellaneous tumours of the brain
Cholosteatoma grade I 1 1 100
Lipoma 1 1 100
Osteoma, benign 1 0 0
B-lymphoma non-Hodgkin 1 1 100
Hemaglioblastoma 1 0 0
Choroid plexus papilloma 1 0 0
Metastatic brain tumours from other
tissues
From breast 2 2 100
From lung 4 2 50
From melanoma 1 1 100
Nonspecific inflammation 10 0
Non-neoplastic brain specimens 20 0
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sintegrity was tested by PCR amplification of the b-actin house-
keeping gene, as we described previously (Spiropoulou et al, 2004).
Real-time RT–PCR for hTERT mRNA quantification
Human telomerase reverse transcriptase mRNA was quantificated
by the use of the LightCycler, Telo TAGGG hTERT quantification
kit on a Light Cycler (both from Roche Molecular Biochemicals;
(Mannheim, Germany) according to the manufacturer’s instruc-
tions.
In short description, telomerase (hTERT)-encoding mRNA was
reversed transcribed and a 198bp fragment (corresponding to the
full-length hTERT transcript) of the generated cDNA was amplified
with specific primers in a one-step RT–PCR reaction. The
amplicon was detected by fluorescence using a specific pair of
hybridisation probes. The hybridisation probes consist of two
different short oligonucleotides that hybridise to an internal
sequence of the amplified fragment during the annealing phase of
the amplification cycle. One probe is labelled at the 50-end with
LightCycler-Red 640, and to avoid extension, modified at the 30-
end by phosphorylation. The other probe is labelled at the 30-end
with fluorescein. The emitted fluorescence of LightCycler-Red 640
was then measured at the instrument LightCycler. In a separate
one-step RT–PCR, mRNA, encoding for porphobilinogen deami-
nase (PBGD), was processed for use as a house-keeping gene. The
reaction product served both as a control for RT–PCR perfor-
mance and as a reference for relative quantification. During initial
optimisation of PCR conditions, amplified products were analysed
using agarose gels to ensure correct product size. Once the PCR
product was determined with Light Cycler melting-curve analysis,
it was used to control for the specificity of amplifications. The
number of transcripts in samples was calculated with the
LightCycler software, using the calibration data obtained from
serial dilutions of purified PCR products containing known
numbers of cDNA molecules of each gene (Figure 1). The results
of real-time PCR were given as the ratio between hTERT and PBGD
transcripts, expressed as a percentage and converted to arbitrary
units dividing by 1000. All experiments were performed in
duplicate, with good consistency of results (the mean coefficient
of variation was 9.5%). All samples were analysed in a blind-trial
fashion.
Statistical analysis
A Cox proportional hazard regression model (Cox, 1972) was
developed to evaluate the association (i.e. hazard ratio and its
confidence interval) between the potential prognostic marker and
progression-free (PFS) or overall survival (OS). This analysis was
conducted at both univariate and multivariate levels. The multi-
variate model was adjusted for hTERT mRNA expression in
tumours, tissue grade and patients age. Survival analysis was
performed by constructing Kaplan–Meier PFS and OS curves
(Kaplan and Meier, 1958) for hTERT-positive and hTERT-negative
patients, and the log-rank test was used to compare survival
between subgroups of patients. Progression-free survival was
defined as the time interval between the date of surgery and the
date of identification of recurrent or metastatic disease. Overall
survival was defined as the time interval between the date of
surgery and the date of death. Other analyses of statistical links
between biological and clinical parameters were performed using
standard tests.
RESULTS
We studied 68 intracranial tumours for the presence of hTERT
mRNA using a real-time RT–PCR. Table 1 presents the classifica-
tion of the samples examined in the study according to WHO
histologic criteria and the percentage of detectable hTERT mRNA
expression in them. The percentage of patients with detectable
hTERT mRNA expression is markedly increased with enhanced
malignancy (Po0.001, Table 4): hTERT mRNA expression was
detected in eight out of 33 samples of low malignancy (24.2%), in
19 out of 27 samples of high malignancy (70.4%) and in five out of
seven samples metastatic to the brain (71.4%) (Table 2). Patient
age ranged from 1 to 76 years with a mean of 48.672.54. human
telomerase reverse transcriptase arbitrary units ranged from
0.018–19.97 with a mean of 1.4470.42 (Table 3). The detection
limit of hTERT was found to be 0.036 arbitrary units and half of
this value (0.018 arbitrary units) was used for the estimation of
negative values for hTERT mRNA. Enlistment of samples as
primary-low malignant, primary-high malignant and metastatic-
high malignant and correlation with hTERT mRNA arbitrary units
expression showed statistical significance (Po0.001) (Table 4)
calculated by the Kruskal–Wallis test. Figure 2 shows that there is
statistically significant correlation (Po0.001) between hTERT
mRNA expression and the grade of the tumours. Progression-free
survival probability is significantly lower for patients having
positive hTERT expression (P¼0.031) (Figure 3). Overall survival
is significantly lower for patients with positive hTERT expression
(P¼0.047) (Figure 4). Cox univariate regression analysis shows
that hTERT-positive patients had a high and statistically
significant risk for relapse (hazard ratio (HR)¼2.24, P¼0.038,
respectively) (Table 5). Human telomerase reverse transcriptase
values were adjusted for tumour grade and patients age in order to
construct the Cox multivariate regression model. Since statistically
significant relationship was found between hTERT mRNA and
tumour grade (Po0.001), hTERT mRNA could not be considered
as an independent prognostic factor for PFS or OS of patients
having intracranial tumours.
DISCUSSION
It seemed reasonable that telomerase expression might be a useful
new prognostic marker in brain tumours, based on numerous
studies in the literature on its prognostic implications in other
tumour types, like breast, colorectal, endometrial, cervical or
ovarian cancer. These studies come to diverse conclusions as to
whether telomerase expression has prognostic utility and empha-
sise that the question needs to be addressed for each individual
tumour type. The present study examines intracranial tumours of
different histotypes as they presented randomly to the Neurosur-
gery Department of the University Hospital of Heraclio at the
island of Crete, between the years 1999 and 2003. Most previous
studies for hTERT expression have employed qualitative rather
than quantitative methods. In regard to brain tumours, Langford
et al (1997) observed a highly significant correlation in ordinary
meningiomas between the presence of telomerase activity and a
poor prognosis for the patient, a finding that was corroborated by
Falchetti et al, 1999. In line with this, Boldrini et al (2003) reported
a significant association between telomerase activity and hTERT
mRNA expression, both tending to increase as the histologic
grading of meningiomas increased, suggesting a role of telomerase
reactivation in the progression of these tumours. In the present
study, four out of 18 meningiomas and three out of eight grade I
meningiomas were positive for hTERT mRNA expression (data not
shown), suggesting also a trend for increased expression with
histologic grading of meningiomas. On the other hand, studies by
Falchetti et al (1999), Harada et al (2000), Cabuy and de Ridder
(2001) and Tchirkov et al (2003) have generated conflicting results
regarding the prognostic utility of telomerase expression in
meningiomas and gliomas (predominantly of high grade).
In this study, we measured the hTERT mRNA level in 68
intracranial tumours using a recently introduced real-time
quantitative PCR technique. We found a progressive increase in
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sthe hTERT detection rate with increasing levels of malignancy
(Po0.001) (Table 4). Present data are coarsely in agreement with
the detection rates of telomerase activity reported for similar
tumour types (DeMasters et al, 1997; Hiraga et al, 1998; Le et al,
1998; Harada et al, 2000; Sugita et al, 2000). The correlation of
hTERT mRNA expression with the level of malignancy is highly
specific when comparing as a group the more aggresssive tumours
(gliomas and metastatic tumours) and tumours regarded usually as
benign (meningiomas, neurinomas) (P¼0.001) (Table 4). This
association is in line with the demonstration of a similar
association at the level of hTERT-protein overexpression (Chakra-
varti et al, 2001). Among patients with detectable levels of hTERT
mRNA, the amount of hTERT transcripts was significantly higher
among glioblastoma patients as well as patients with metastatic
tumours to the brain in comparison to patients with other tumour
histotypes (data not shown). Unfortunately, the small number of
samples present in each category does not allow separate statistical
correlation for patients operated for neuroepithelial, meningial or
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Figure 1 Example of real-time RT–PCR quantification of hTERT mRNA in tumour samples. Top, hTERT standard curve; bottom, hTERT analysis
(htertst1, 2, 3, 4, 5 are human TERT RNA Standards with concentration of 7.3 10
5, 7.0 10
4,8,5 10
3, 8.4 10
2, 8.1 10
1 copies per 2ml, respectively;
Positcontrol¼positive control RNA; negat¼negative control; samples 1–11 correspond to intracranial tumour samples).
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smetastatic tumours with their survival. Nevertheless, not all
glioblastomas or all of metastatic tumours to the brain were found
to express hTERT transcripts. Similar results have been reported
from other authors. Tchirkov et al (2003), using the same method,
reported hTERT mRNA-positive expression in 69.8% of glioblas-
toma multiforme samples, when in the present study we found
66.6%. Kleinschmidt-DeMasters et al (2000) analysed by the TRAP
method and found hTERT expression in 89% of glioblastoma
samples. All of those results are discordant with the conclusion of
Falchetti et al (1999) that the assessment of telomerase activity
influence tumour prognosis in malignant gliomas. Kleinschmidt-
DeMasters et al (2000) addressed this question by analysing
quantitatively two to three regions from each tumour and found
three-fold regional variation in telomerase levels within the same
tumour. They concluded that even in glioblastomas that show
positivity for telomerase expression, there is variability in the level
of telomerase expression from region to region within the tumour.
They observed that areas of tissue were negative for telomerase
expression when they contained small number of tumour cells.
Some negative telomerase-expressing glioblastoma or metastatic
samples of our study possibly are taken from infiltrating edge of
tumours, where smaller numbers of tumour cells were present
relative to reactive or normal tissue or from areas with extensive
necrosis. Two out of the seven metastatic brain tumours examined
in the present study were negative for hTERT mRNA expression,
Table 2 Classification of tumours examined for human telomerase
reverse transcriptase (hTERT) mRNA expression according to their
histologic malignancy status
No. of
samples
+ hTERT mRNA
expression
Low malignancy
Meningiomas 18 4
Neurinomas 4 1
Ependymoma (grade I) 1 0
Astrocytomas (grade I) 5 1
Haemaglioblastoma 1 0
Osteoma 1 0
Lipoma 1 1
Cholosteatoma 1 1
Choroid plexus papilloma 1 0
Total 33 8
High malignancy
Glioblastoma 17 10
Myeloblastoma 2 2
Ependymoma (grade II) 1 1
Astrocytoma (grade II or III) 3 3
B-lymphoma non-Hodgkin 1 1
Oligodendroglioma 3 2
Total 27 19
Nonspecific inflammation 10
Metastatic from other tissues 7 5
Table 3 Descriptive statistics of continuous variables of the study
Percentiles
10 25 50 75 90
Variable Mean7s.e.
a Range (Median)
hTERT (arbitrary units) 1.4470.42 0.018–19.97 0.018 0.018 0.036 0.88 4.64
Age (years) 48.6172.54 1–76 13.8 32.2 54.5 65.7 73.1
aStandard error.
Table 4 Human telomerase reverse transcriptase (hTERT) mRNA (arbitrary units) distribution in low and high malignant potential brain tumours
Tumour Mean7s.e.
a Median Range P-value
b
Primary low malignant brain tumours (N¼33) 0.3170.20 0.017 0.018–6.13
Primary high malignant brain tumours (N¼27) 2.1170.68 0.37 0.018–14.06 o0.001
Metastatic high malignant brain tumours (N¼7) 4.5472.76 1.16 0.018–19.97
aStandard error.
bCalculated by Kruskal–Wallis test.
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Figure 2 Association of hTERT mRNA expression, defined in arbitrary
units, with tumour grade. P-value was calculated by Mann–Whitney test.
Horizontal lines represent the mean.
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swhenever the positive samples showed a great variability in the
expression levels of hTERT mRNA. The time interval to demise for
all patients with metastatic tumours was from 6 to 12 months (data
not shown). Although the number of metastatic brain tumours in
the present study is small, there is a similarity with the results of
Kleinschmidt-DeMasters et al (1998) reporting a four-fold
logarithmic variability but no correlation with tumour type or
interval to demise.
In conclusion, the present study revealed statistical correlation
between hTERT mRNA expression levels and the grade of the
tumours (examined regardless of their histotypes) (Po0.001)
(Figure 2). In our study, patients of all histological types having
negative expression of hTERT mRNA had statistically longer PFS
(P¼0.031) (Figure 3) and OS (P¼0.047) (Figure 4). Cox
univariate regression analysis showed that hTERT mRNA-positive
patients had a high and statistically significant risk of relapse (HR
of 2.24 and P¼0.038) (Table 5). In the Cox multivariate regression
model, the levels of hTERT mRNA were adjusted for tumour grade
and patients age. Since there was statistically significant relation-
ship between the levels of hTERT mRNA and the grade of the
tumours (P¼0.003 or P¼0.006, respectively), hTERT mRNA
levels could not be considered as an independent prognostic factor
for PFS or OS.
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Figure 3 Kaplan–Meier curve for PFS of patients with hTERT mRNA-
positive and hTERT mRNA-negative intracranial tumours.
Table 5 Univariate and multivariate analysis of human telomerase reverse transcriptase (hTERT) mRNA status with regard to progression-free and overall
survival
Variable
Progression-free survival Overall survival
HR
a 95% CI
b P-value HR
a 95% CI
b P-value
Univariate analysis
hTERT mRNA
Negative 1.00 1.00
Positive 2.24 1.046–4.97 0.038 2.26 0.97–5.24 0.057
log hTERT(continuous variable) 1.51 1.081–2.13 0.016 1.44 0.99–2.11 0.056
Grading (ordinal) 2.49 1.68–3.69 o0.001 2.38 1.57–3.61 o0.001
Age 1.02 1.00–1.04 0.031 1.03 1.00–1.05 0.022
Multivariate analysis
c
hTERT mRNA
Negative 1.00 1.00
Positive 0.71 0.31–1.63 0.42 0.83 0.33–2.04 0.68
hTERT (continuous variable) 1.05 0.91–1.11 0.92 0.99 0.89–1.10 0.84
Grading (ordinal) 2.51 1.64–3.81 o0.001 2.34 1.51–3.65 o0.001
Age 1.02 0.99–1.05 0.075 1.03 1.00–1.06 0.028
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConfidence interval of the estimated HR.
cMultivariate models were adjusted for tumour grade
and patient age.
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Figure 4 Kaplan–Meier curve for OS of patients with hTERT mRNA-
positive and hTERT mRNA-negative intracranial tumours.
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